Supernus to Present at the 2018 Cowen Health Care Conference
07 March 2018 - 8:15AM
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty
pharmaceutical company focused on developing and commercializing
products for the treatment of central nervous system diseases,
today announced that the Company's management will present an
overview and update for the Company, and host investor meetings, at
the Cowen 38th Annual Health Care Conference.
Date: Tuesday, March 13, 2018Time: 10:00 a.m. ETPlace: The
Boston Marriott Copley Place, Boston, Mass.
Investors interested in arranging a meeting with the Company's
management during this conference should contact the conference
coordinator.
A live webcast of the presentation can be accessed by visiting
‘Events & Presentations’ in the Investor Relations Section on
the Company's website at www.supernus.com. An archived replay of
these webcasts will be available for 60 days after the conference
on the Company's website.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on developing and commercializing products for the
treatment of central nervous system diseases. The Company currently
markets Trokendi XR® (extended-release topiramate) for the
prophylaxis of migraine headache and the treatment of epilepsy, and
Oxtellar XR® (extended-release oxcarbazepine) for the treatment of
epilepsy. The Company is also developing several product candidates
to address large market opportunities in psychiatry, including
SPN-810 for the treatment of Impulsive Aggression in ADHD patients
and SPN-812 for the treatment of ADHD.
CONTACT:Jack A. Khattar, President and CEOGregory S. Patrick,
Vice President and CFOSupernus Pharmaceuticals, Inc.Tel: (301)
838-2591
Or
Investor Contact:Peter VozzoWestwicke PartnersOffice: (443)
213-0505Mobile: (443) 377-4767Email: peter.vozzo@westwicke.com
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Apr 2024 to May 2024
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From May 2023 to May 2024